Shots:
- The company will highlight data from P-I/II (CLINCH) trial of ATN-022 to treat advanced/metastatic gastric cancer in Australia & China at ASCO GI 2025 under the title, ‘Safety and Preliminary Efficacy of ATG-022 in Patients with Advanced/Metastatic Gastric Cancer (CLINCH)’
- In the dose expansion phase (as of Nov 2024), 21 patients with CLDN18.2 expression IHC 2+ ≥20% had 42.9% ORR (9 PRs incl. 8 confirmed PRs, 11 SDs) & 95.2% DCR, while 10 patients with IHC 2+ <20% on 1.8–2.4mg/kg doses had 30% ORR (1 CR with durable response for over 14mos., 2 PRs) & 50% DCR
- ATN-022 showed a manageable safety, supporting further development. Enrollment for dose optimization & other solid tumors is ongoing in China & Australia
Ref: Antennova | Image: Antennova
Related News:- Yoltech Initiates a Dose-Escalation Study for YOLT-204 to Treat β -Thalassemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
